Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+ CD25+ T cells: a double‐blind placebo‐controlled study
- 7 September 2004
- Vol. 59 (10), 1097-1101
- https://doi.org/10.1111/j.1398-9995.2004.00601.x
Abstract
We have previously described both modification of allergen immunotherapy using peptide fragments, and reduced regulation of allergen stimulated T cells by CD4(+) CD25(+) T cells from allergic donors when compared with nonallergic controls. It has been suggested that allergen immunotherapy induces regulatory T cell activity: we hypothesized that allergen peptide immunotherapy might increase suppressive activity of CD4(+) CD25(+) T cells. To examine cat allergen-stimulated CD4 T cell responses and their suppression by CD4(+) CD25(+) T cells before and after cat allergen peptide immunotherapy in a double-blind placebo-controlled study. Peripheral blood was obtained and stored before and after peptide immunotherapy or placebo treatment. CD4(+) and CD4(+) CD25(+) were then isolated by immunomagnetic beads and cultured with allergen in vitro. Comparing cells from blood taken before with that after peptide immunotherapy there was a significant reduction in both proliferation and IL-13 production by allergen-stimulated CD4+ T cells, whereas no change was seen after placebo. CD4(+) CD25(+) T cells suppressed both proliferation and IL-13 production by CD4(+) CD25(-) T cells before and after therapy but peptide therapy was not associated with any change in suppressive activity of these cells. Allergen peptide immunotherapy alters T cell response to allergen through mechanisms other than changes in CD4(+) CD25(+) T cell suppression.Keywords
This publication has 29 references indexed in Scilit:
- IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapyEuropean Journal of Immunology, 2003
- In Vitro Generation of Interleukin 10–producing Regulatory CD4+ T Cells Is Induced by Immunosuppressive Drugs and Inhibited by T Helper Type 1 (Th1)– and Th2-inducing CytokinesThe Journal of Experimental Medicine, 2002
- Interleukin-10 and the Interleukin-10 ReceptorAnnual Review of Immunology, 2001
- Allergy and Allergic DiseasesNew England Journal of Medicine, 2001
- Regulatory T CellsCell, 2000
- Long-Term Clinical Efficacy of Grass-Pollen ImmunotherapyNew England Journal of Medicine, 1999
- Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trialClinical and Experimental Allergy, 1997
- IL‐13 production by allergen‐stimulated T cells is increased in allergic disease and associated with IL‐5 but not IFN‐γ expressionImmunology, 1997
- Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs.BMJ, 1991
- CSM Update: Desensitising vaccinesBMJ, 1986